Group 1 - The core viewpoint of the article highlights the recent strong performance of several biopharmaceutical stocks, particularly in the Hong Kong market, with innovative drug concepts becoming increasingly active [1] - WuXi AppTec (药明合联) led the sector with a rise of over 8%, while WuXi Biologics (药明生物) increased by over 5%, and other companies like CanSino Biologics (康方生物), Genscript Biotech (云顶新耀), and Innovent Biologics (诺诚健华) saw gains exceeding 4% [1] - According to Guolian Minsheng Securities, the innovative drug business development (BD) transactions in China are expected to continue the high growth trend seen in 2025, indicating a robust upward momentum in the industry [1] Group 2 - The stock performance data shows that WuXi AppTec (02268) increased by 8.40% to a latest price of 63.250, with a total market capitalization of 795.68 billion [2] - WuXi Biologics (02269) rose by 5.38% to 40.340, with a market cap of 1,669.08 billion, reflecting a year-to-date increase of 28.31% [2] - Other notable performers include CanSino Biologics (09926) up by 4.81%, Genscript Biotech (01952) up by 4.27%, and Innovent Biologics (69660) up by 4.04%, indicating a positive trend across the sector [2]